C02: Controversies in the Management of Symptomatic Carotid Stenosis/Update on the CREST 2 Trial

Moderator(s)

• 

  Ali AbuRahma, MD

  Professor of Surgery
  WVU/Charleston Area Medical Center
  Charleston, West Virginia
• 

  Ravi Rajani, MD (he/him/his)

  Executive Associate Dean
  Emory University School of Medicine
  Atlanta, Georgia

With the recent approval of CMS covering transfemoral carotid artery stenting for symptomatic patients even in standard risk patients, the management of symptomatic carotid stenosis has become somewhat controversial. Most authorities still believe carotid endarterectomy combined with medical therapy is the optimal and first line of intervention while others advocate transcarotid artery revascularization or transfemoral carotid artery stenting in standard risk patients. This session will delineate all these options and the pros and cons of each. In addition, since the CREST 2 trial has been completed and perhaps the results will be shown by the end of the year, it is only logical to include this data in this session.

Presentations:

• 3:15 PM - 3:23 PM ET

  CEA Should be the First Line of Therapy in a Standard Risk Patient
  

  Speaker: Caron Rockman, MD
• 3:23 PM - 3:31 PM ET

  TCAR Should be the First Line of Therapy in Standard Risk Patients
  

  Speaker: Mahmoud B. Malas, MD (he/him/his) – University of California San Diego
• 3:31 PM - 3:39 PM ET

  TFCAS Should be the First Line of Therapy in Standard Risk Patients
  

  Speaker: Jon S. Matsumura, MD – University of Colarado
• 3:39 PM - 3:47 PM ET

  Carotid Intervention Should be Selected According to Risk Stratification
  

  Speaker: Richard J. Powell, MD – Section of Vascular Surgery, Heart and Vascular Center, Dartmouth Hitchcock Medical Center, Lebanon, NH
• 3:47 PM - 3:55 PM ET

  Is Carotid Artery Stenting Better with a MicroNet Mesh?
  

  Speaker: Patrick Muck, MD – Good Samaritan Hospital
• 3:55 PM - 4:03 PM ET

  Eversion or Patch? Choosing the Optimal Technique in Carotid Endarterectomy
  

  Speaker: Ralph Clement Darling, III, MD – Albany Medical Center
• 4:03 PM - 4:11 PM ET

  Status of CREST 2 and Role of Best Medical Therapy in Standard Risk Patients
  

  Speaker: Brajesh K. Lal, MD – University of Maryland School of Medicine, Baltimore, MD, USA
• 4:11 PM - 4:19 PM ET

  CEA is Still Alive After CREST 2, Let’s Examine the Evidence
  

  Speaker: Ali F. AbuRahma, MD – WVU/Charleston Area Medical Center
• 4:20 PM - 4:45 PM ET

  Discussion